Frexalimab
Based on 1 Customer Validation
Frexalimab (SAR441344) is a second-generation monoclonal antibody targeting the CD40 ligand (CD40L) with a good safety profile. Frexalimab inhibits the binding between CD40 and CD40L to modulate immune response. Frexalimab is likely to help prevent the process of β-cell destruction. Frexalimab is proming for multiple sclerosis, lupus erythematosus, Sj gren’s syndrome and type I diabetes research.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.00%
- No. CAS: 2515463-86-0
- Peso molecular:145.698 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Ver todos los productos específicos de isoformas TNF Receptor
More
Actividad biológica
Descripciòn
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
CD40LG
In Vitro
Frexalimab is a second-generation anti-CD40L humanized IgG1 monoclonal antibody that has been Fc-engineered. The Fc engineering abrogates the platelet activation that is triggered by FcγRIIa stimulation by immune complexes[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Aplicación
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow cytometric analysis of 1X10EC6 500 ng/mL anti-CD3 stimulated Jurkat cells(24h) with Frexalimab (HY-P99625, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black). -
Immobilized Human CD40 Ligand/TNFSF5 Protein (His Tag) can bind Frexalimab. The EC50 for this effect is 2.43 ng/mL. -
Loaded Frexalimab on AHC2 biosensor, can bind CD40L/CD154/TRAP Protein, Human (HEK293, Tag free, HY-P70609) with an affinity constant of 4.117E-10 M as determined in BLI assay.
Chemical Information
-
No. CAS 2515463-86-0
-
Appearance Liquid
-
Peso molecular 145.698 kDa
-
Color Colorless to light yellow
-
SMILES
[Frexalimab]
-
Synonyms
SAR441344; INX-021
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (258 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
[1]. Bruce A C Cree, et al. New drugs for multiple sclerosis: new treatment algorithms. Curr Opin Neurol. 2022 Jun 1;35(3):262-270. [Content Brief]
[2]. Vermersch P, et al. Inhibition of CD40L with Frexalimab in Multiple Sclerosis. N Engl J Med. 2024 Feb 15;390(7):589-600. [Content Brief]
[3]. Carvalho T. Anti-CD40L antibody frexalimab slows new brain lesions in multiple sclerosis. Nat Med. 2023 Aug;29(8):1882-1883. [Content Brief]
[4]. Weiskorn J, et al. Moving from Insulin Substitution to the Treatment of the Underlying Autoimmune Disease in Type 1 Diabetes. Horm Res Paediatr. 2024 Apr 30:1-8. [Content Brief]
[5]. Maddaloni E, et al. Immune checkpoint modulators in early clinical development for the treatment of type 1 diabetes. Expert Opin Investig Drugs. 2024 Apr;33(4):303-318. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)